<DOC>
	<DOCNO>NCT02027870</DOCNO>
	<brief_summary>The study aim assess safety , efficacy performance delivery system new generation Sirolimus-eluting stent JWMS five year .</brief_summary>
	<brief_title>EXCEL-II DES Treat Patients With de Novo Coronary Artery Lesions . ( CREDIT-III )</brief_title>
	<detailed_description>1 . A prospective , single set , multicenter clinical trial ; 2 . The primary situ patient coronary heart disease ; 3 . The center : 28 ( actual number center shall prevail ) ; The plan select 621 patient ; ( total number case 2.25 mm specification le 30 case , 5 case specification le 2.25 mm . ) 4 . Clinical follow-up time point : 1 month , 6 month , 12 month 18 month year 2 year 5 year follow-up ; This test independent coronary angiography core laboratory , data management statistical center , clinical end point judge committee clinical monitoring relevant clinical imaging data collecting , sort , statistical analysis judgement.All select patient within five year continuous follow-up tracking ( phone outpatient follow-up ) , observe happen adverse event forward second generation EXCEL drug-eluting stent ( de ) system security make accurate credible evaluation .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion criterion : 1.18yrs≤Age≤75yrs . 2..stability unstable angina pectoris ( AP ) , chronic myocardial infarction ( OMI ) confirm ( myocardial ischemia ; 3.De novo lesion native coronary artery ( Up four target lesion ) . 4.Lesion length ≤60mm . 5.RVD 2.25mm～4.0mm . 6.DS % ≥70 % visual estimation . 7.Coronary artery bypass surgery ( coronary artery bypass graft ) patient . 8.Subjects willing follow specify requirement followup . 9.To understand purpose testing , voluntary sign informed consent , willing accept image clinical followup subject . 1 . AMI within 7 day . 2 . Left main lesion , transplant vasculopathy stent restenosis lesion ; 3 . Severe calcified lesion unable predilate . 4 . The distortion stent hamper lesion . 5 . NYHA≥Ⅲ LVEF＜35 % . 6 . Prior stenting within 1 year . 7 . Pregnancy lactation , plan postoperative pregnancy lactation . 8 . Subjects bleed tendency blood coagulation dysfunction PCI contraindication , anticoagulant therapy taboo ca n't continue DAPT healer least 1 year . 9 . There diseases ( cancer , malignant tumor , congestive heart failure , organ transplantation candidate ) abuse history ( alcohol cocaine heroin , etc . ) , scheme compliance poor , interference relate data explanation limited life ( &lt; 1 year ) . 10 . To aspirin heparin clopidogrel cobalt chromium alloy rapamycin PLA polymer contrast agent one allergy . 11 . Serious liver kidney function complete person ( ALT AST three time great upper limit normal ) . 12 . Rounding top participate clinical trial reach main research finish time limit . 13 . The researcher determine adherence poor , could finish study accordance requirement subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>DES</keyword>
	<keyword>CAD</keyword>
	<keyword>EXCEL-II</keyword>
	<keyword>JWMS</keyword>
	<keyword>PCI</keyword>
</DOC>